Hydroxyurea Optimization through Precision Study (HOPS): study protocol for a randomized, multicenter trial in children with sickle cell anemia
Authors:
- Emily R. MeierEMEmily R. Meier
- Susan E. CrearySCSusan E. Creary
- Matthew M. HeeneyMHMatthew M. Heeney
- Min DongMDMin Dong
- Abena O. Appiah-KubiAAAbena O. Appiah-Kubi
- Stephen C. NelsonSNStephen C. Nelson
- Omar NissONOmar Niss
- Connie PicconeCPConnie Piccone
- Maa-Ohui QuarmyneMQMaa-Ohui Quarmyne
- Charles T. QuinnCQCharles T. Quinn
- Kay L. SavingKSKay L. Saving
- John P. ScottJSJohn P. Scott
Open Access
- 27 November 2020
- journal article
- research article
- Published by Springer Nature in Trials
- Vol. 21 (1) , 1-14
Abstract
Background: Sickle cell disease (SCD) is a severe and devastating hematological disorder that affects over 100,000 persons in the USA and millions worldwide. Hydroxyurea is the primary disease-modifying therapy for the SCD, with proven benefits to reduce both short-term and long-term complications. Despite the well-described inter-patient variability in pharmacokinetics (PK), pharmacodynamics, and optimal dose, hydroxyurea is traditionally initiated at a weight-based dose with a subsequent conservative dose escalation strategy to avoid myelosuppression. Because the dose escalation process is time consuming and requires frequent laboratory checks, many providers default to a fixed dose, resulting in inadequate hydroxyurea exposure and suboptimal benefits for many patients. Results from a single-center trial of individualized, PK-guided dosing of hydroxyurea for children with SCD suggest that individualized dosing achieves the optimal dose more rapidly and provides superior clinical and laboratory benefits than traditional dosing strategies. However, it is not clear whether these results were due to individualized dosing, the young age that hydroxyurea treatment was initiated in the study, or both. The Hydroxyurea Optimization through Precision Study (HOPS) aims to validate the feasibility and benefits of this PK-guided dosing approach in a multi-center trial.Methods: HOPS is a randomized, multicenter trial comparing standard vs. PK-guided dosing for children with SCD as they initiate hydroxyurea therapy. Participants (ages 6 months through 21 years), recruited from 11 pediatric sickle cell centers across the USA, are randomized to receive hydroxyurea either using a starting dose of 20 mg/kg/day (Standard Arm) or a PK-guided dose (Alternative Arm). PK data will be collected using a novel sparse microsampling approach requiring only 10 μL of blood collected at 3 time-points over 3 h. A protocol-guided strategy more aggressive protocols is then used to guide dose escalations and reductions in both arms following initiation of hydroxyurea. The primary endpoint is the mean %HbF after 6 months of hydroxyurea.Discussion: HOPS will answer important questions about the clinical feasibility, benefits, and safety of PK-guided dosing of hydroxyurea for children with SCD with potential to change the treatment paradigm from a standard weight-based approach to one that safely and effectively optimize the laboratory and clinical response.Trial registration: ClinicalTrials.govNCT03789591. Registered on 28 December 2018.Keywords
All Related Versions
Funding Information
- Doris Duke Charitable Foundation (2017090)
This publication has 41 references indexed in Scilit:
- Global Burden of Sickle Cell Anaemia in Children under Five, 2010–2050: Modelling Based on Demographics, Excess Mortality, and InterventionsPLOS Medicine, 2013
- The effect of hydroxcarbamide therapy on survival of children with sickle cell diseaseBritish Journal of Haematology, 2013
- Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimatesThe Lancet, 2013
- Stroke With Transfusions Changing to Hydroxyurea (SWiTCH)Blood, 2012
- Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemiaBlood, 2011
- Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimenOrphanet Journal of Rare Diseases, 2011
- Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain?Current Opinion in Hematology, 2011
- Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)The Lancet, 2011
- The risks and benefits of long‐term use of hydroxyurea in sickle cell anemia: A 17.5 year follow‐upAmerican Journal of Hematology, 2010
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009